Comparative Efficacy and Safety of Vancomycin versus Teicoplanin: Systematic Review and Meta-Analysis

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2009-07-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1128/AAC.00341-09PMID 19596875PMCID PMC2764163
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cost Analysis of 2 Empiric Antibacterial Regimens Containing Glycopeptides for the Treatment of Febrile Neutropenia in Patients with Acute Leukaemia

  2012cited by this paper
• Cochrane Handbook for Systematic Reviews of Interventions

  2010influential reference
• Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season.

  2009cited by this paper
• Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

  2009cited by this paper
• Epidemiology of methicillin-resistant Staphylococcus aureus.

  2008influential reference
• Larger Vancomycin Doses (at Least Four Grams per Day) Are Associated with an Increased Incidence of Nephrotoxicity

  2008cited by this paper
• Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta‐Analysis

  2008cited by this paper
• Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006.

  2008cited by this paper
• Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis.

  2008cited by this paper
• Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.

  2008cited by this paper
• Invasive Methicillin-Resistant Staphylococcus aureus Infections in the United States

  2008cited by this paper
• Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community.

  2008cited by this paper
• Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin

  2008cited by this paper
• Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.

  2008cited by this paper
• The prevalence of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) in skin abscesses presenting to the pediatric emergency department.

  2008influential reference
• The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus.

  2007cited by this paper
• Vancomycin In Vitro Bactericidal Activity and Its Relationship to Efficacy in Clearance of Methicillin-Resistant Staphylococcus aureus Bacteremia

  2007cited by this paper
• Invasive methicillin-resistant Staphylococcus aureus infections in the United States.

  2007cited by this paper
• Prevalence and Characteristics of Heteroresistant Vancomycin-Intermediate Staphylococcus aureus Bacteremia in a Tertiary Care Center

  2007cited by this paper
• Use of 27 parenteral antimicrobial agents in north of France hospitals.

  2007cited by this paper
• Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.

  2007cited by this paper
• Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 Study

  2006cited by this paper
• High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.

  2006cited by this paper
• Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002.

  2006cited by this paper
• Staphylococcus aureus in community-acquired pneumonia.

  2006influential reference
• Glycopeptides: Update on an old successful antibiotic class.

  2006cited by this paper
• Glycopeptide and lipoglycopeptide antibiotics.

  2005cited by this paper
• Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.

  2005cited by this paper
• Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens.

  2005cited by this paper
• Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.

  2005cited by this paper
• Safety and efficacy of glycopeptide antibiotics.

  2005cited by this paper
• Addition of Teicoplanin or Vancomycin for the Treatment of Documented Bacteremia due to Gram-Positive Cocci in Neutropenic Patients with Hematological Malignancies: Microbiological, Clinical and Economic Evaluation

  2004cited by this paper
• Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia

  2004cited by this paper
• Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.

  2003cited by this paper
• Outcomes of an intervention to improve hospital antibiotic prescribing: interrupted time series with segmented regression analysis.

  2003cited by this paper
• Red man syndrome

  2002cited by this paper
• Vancomycin resistant Staphylococcus aureus in the United States

  2002cited by this paper
• Le coût comparatif du traitement par vancomycine versus teicoplanine dans l'infection ostéoarticulaire à staphylocoques résistants à la méticilline

  2001cited by this paper
• Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin.

  2001cited by this paper
• Glycopeptide resistance among coagulase-negative staphylococci that cause bacteremia: epidemiological and clinical findings from a case-control study.

  2001cited by this paper
• Evaluation of Current Methods for Detection of Staphylococci with Reduced Susceptibility to Glycopeptides

  2001cited by this paper
• [The comparative costs of vancomycin treatment versus teicoplanin in osteoarticular infection caused by methicillin-resistant staphylococci].

  2001cited by this paper
• Performance standards for antimicrobial susceptibility testing

  2001cited by this paper
• Systematic reviews in health care : meta-analysis in context

  2001cited by this paper
• Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome.

  2000cited by this paper
• Comparison of Efficacy and Safety of Teicoplanin and Vancomycin in Children with Antineoplastic Therapy-Associated Febrile Neutropenia and Gram-Positive Bacteremia

  2000cited by this paper
• Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.

  1999cited by this paper
• Prospective, double-blind, randomized trial of teicoplanin versus vancomycin for the therapy of vascular access-associated bacteremia caused by gram-positive pathogens

  1999cited by this paper
• Ceftazidime plus amikacin plus teicoplanin or vancomycin in the empirical antibiotic therapy in febrile neutropenic cancer patients.

  1998cited by this paper
• PP5. Teicoplanin or vancomycin in febrile neutropenic children with cancer: A randomized cost effectiveness study

  1997cited by this paper
• [Imipenem combined with teicoplanin or vancomycin in the initial empirical treatment of febrile neutropenia. Analysis of the primary response and of a global sequential strategy in 126 episodes].

  1996cited by this paper
• The comparative efficacy and safety of teicoplanin and vancomycin.

  1996cited by this paper
• The comparative efficacy and safety of teicoplanin and vancomycin.

  1996cited by this paper
• Comparative Study of Teicoplanin vs Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteraemia

  1996cited by this paper
• Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus.

  1995cited by this paper
• Teicoplanin vs. vancomycin for the treatment of serious infections: a randomised trial.

  1995cited by this paper
• Teicoplanin: a well-tolerated and easily administered alternative to vancomycin for Gram-positive infections in intensive care patients

  1994cited by this paper
• A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of gram-positive bacteremia in patients with cancer.

  1994cited by this paper
• Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program

  1994cited by this paper
• Teicoplanin versus vancomycin in the empirical treatment of febrile neutropenic patients

  1993cited by this paper
• Absence of "red man syndrome" in patients being treated with vancomycin or high-dose teicoplanin

  1992cited by this paper
• The Use of Glycopeptides as Empiric Antibiotic Therapy in Febrile Neutropenic Patients: A Comparison Between Teicoplanin (TEI) and Vancomycin (VAN)

  1992cited by this paper
• Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity

  1991cited by this paper
• Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts

  1991cited by this paper
• Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon

  1991cited by this paper
• A prospective study comparing vancomycin and teicoplanin as second‐line empiric therapy for infection in neutropenic patients

  1990cited by this paper
• Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters

  1989cited by this paper
• Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results.

  1988cited by this paper
• National Committee for Clinical Laboratory Standards.

  1980cited by this paper
• Annals of Clinical Microbiology and Antimicrobials Laboratory-based Surveillance of Current Antimicrobial Resistance Patterns and Trends among Staphylococcus Aureus: 2005 Status in the United States

  year unknowncited by this paper

• Population pharmacokinetics and dosing optimization of teicoplanin in renal transplant patients

  2025cites this paper
• Evaluating anti-MRSA antibiotic stewardship with a focus on trends in consumption and resistance in a tertiary hospital in Alexandria, Egypt from 2019 to 2023

  2025cites this paper
• Comparative Risk of Acute Kidney Injury with Piperacillin–Tazobactam Plus Teicoplanin Versus Piperacillin–Tazobactam Plus Vancomycin: A Systematic Review and Meta-Analysis

  2025cites this paper
• Soaking in Povidone-Iodine, Chlorhexidine, Teicoplanin, Vancomycin, and Saline Solution Differentially Alters Porcine Flexor Tendon Size and Biomechanical Properties

  2025cites this paper
• Evaluation of teicoplanin protein-binding variability and clinical utility of its free serum concentration measurement

  2025cites this paper
• Appropriateness of loading dose and TDM in patients treated with teicoplanin: a single-centre observational retrospective cohort study comparing single-daily and thrice-weekly regimens.

  2025cites this paper
• Comparison of clinical outcomes of antibiotics used for Staphylococcus aureus bacteremia in pediatric patients

  2025cites this paper
• Optimization of Teicoplanin Dosing Regimen in Adult Patients Using an Externally Evaluated Population Pharmacokinetic Model.

  2025cites this paper
• Teicoplanin 24-h loading dose regimen using a decision tree model to target serum trough concentration of 15-30 μg/mL: a retrospective study.

  2024cites this paper
• Risk Factors for Teicoplanin-Associated Acute Kidney Injury in Patients with Hematological Malignancies: Focusing on Concomitant Use of Tazobactam/Piperacillin.

  2024cites this paper
• Epidemiology and Management of Infections in Liver Transplant Recipients

  2024cites this paper
• Prominent Classes of Antibiotics and their Mechanism of Resistance against Methicillin-Resistant Staphylococcus aureus

  2024cites this paper
• Early Therapeutic Drug Monitoring Optimizes Teicoplanin Use in Febrile Neutropenic Patients with Hematological Malignancies

  2024cites this paper
• Tricalcium phosphate-loaded injectable hydrogel as a promising osteogenic and bactericidal teicoplanin-delivery system for osteomyelitis treatment: An in vitro and in vivo investigation.

  2024cites this paper
• The CssRS two-component system of Bacillus subtilis contributes to teicoplanin and polymyxin B response

  2024cites this paper
• Epidemiology and Outcomes of Infected Non-Unions: An Observational Study at an Infectious Disease Referral Centre

  2024cites this paper
• Rare and unexpected cause for retropharyngeal abscess in an immunocompetent man: metastatic community-acquired methicillin-resistant Staphylococcus aureus infection

  2023cites this paper
• Bayesian prediction-based individualized dosing of anti-methicillin-resistant Staphylococcus aureus treatment: Recent advancements and prospects in therapeutic drug monitoring.

  2023cites this paper
• Acute bacterial skin and skin structure infections in pediatric patients: potential role of dalbavancin

  2023cites this paper
• Teicoplanin and vancomycin as treatment for glycopeptide-susceptible Enterococcus faecium bacteraemia: a propensity score-adjusted non-inferior comparative study

  2023cites this paper
• Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future

  2023cites this paper
• A retrospective analysis to estimate trough concentrations of teicoplanin in patients with suspected or documented Gram-positive infections

  2023cites this paper
• Personalized application of antimicrobial drugs in pediatric patients with augmented renal clearance: a review of literature

  2023cites this paper
• Pharmacist-Driven Dosing Services and Pharmaceutical Care Increase Probability of Teicoplanin Target Concentration Attainment and Improve Clinical and Economic Outcomes in Non-Critically Ill Patients

  2023cites this paper
• Teicoplanin-Resistant Coagulase-Negative Staphylococci: Do the Current Susceptibility Testing Methods Reliably Detect This Elusive Phenotype?

  2023cites this paper
• Pharmacovigilance Study on Eosinophilic Pneumonia Induced by Anti-MRSA Agents: Analysis Based on the FDA Adverse Event Reporting System

  2023cites this paper
• Trends in teicoplanin loading dose implementation from 2010 to 2019 and evaluation of safety and efficacy factors: a retrospective cohort study based on a Japanese administrative claims database

  2023cites this paper
• TIGAR Protects Cochlear Hair Cells against Teicoplanin-Induced Damage

  2023cites this paper
• Accuracy of Therapeutic Drug Monitoring of Teicoplanin at the Onset of Febrile Neutropenia

  2023influential citation
• Optimal Teicoplanin Dosage Regimens in Critically Ill Patients: Population Pharmacokinetics and Dosing Simulations Based on Renal Function and Infection Type

  2023cites this paper
• Second-line antibiotic agents in patient-reported penicillin or cephalosporin allergy have no negative impact on antibiotic resistance after hip and knee arthroplasty.

  2023cites this paper
• Impact of antimicrobial drug-drug interactions on acute kidney injury after allogeneic hematopoietic cell transplantation.

  2023cites this paper
• Safety of high loading doses of teicoplanin: POSY-TEICO, a prospective, multicentre, observational study.

  2023cites this paper
• Drug–drug interaction signals between loop diuretics and teicoplanin during acute kidney injury evaluated using Japanese spontaneous adverse drug event reports

  2023cites this paper
• Optimal Use and Need for Therapeutic Drug Monitoring of Teicoplanin in Children: A Systematic Review

  2023cites this paper
• Comparison of mortality and clinical failure rates between vancomycin and teicoplanin in patients with methicillin-resistant Staphylococcus aureus pneumonia

  2022cites this paper
• Current and emerging drug treatment strategies to tackle invasive community-associated methicillin-resistant Staphylococcus aureus (MRSA) infection: what are the challenges?

  2022cites this paper
• Glycopeptide and Lipoglycopeptide Antibiotics

  2022cites this paper
• Piperacillin–Tazobactam Plus Vancomycin-Associated Acute Kidney Injury in Adults: Can Teicoplanin or Other Antipseudomonal Beta-Lactams Be Remedies?

  2022cites this paper
• Natural Products Lysobactin and Sorangicin A Show In Vitro Activity against Mycobacterium abscessus Complex

  2022cites this paper
• Pharmacokinetics of Teicoplanin in a Patient with Coronavirus Disease 2019 Receiving Veno-venous Extracorporeal Membrane Oxygenation

  2022cites this paper
• Recent Advances in the Development of Semisynthetic Glycopeptide Antibiotics: 2014–2022

  2022cites this paper
• Use of Antibiotics in Preterm Newborns

  2022cites this paper
• Pharmacokinetics and pharmacodynamics of peptide antibiotics.

  2022cites this paper
• Prescription-Event Monitoring Study on Safety and Efficacy of Levonadifloxacin (Oral and I.V.) in Management of Bacterial Infections: Findings of Real-World Observational Study

  2022cites this paper
• Methicillin Resistant S. aureus (MRSA) Bacteremia: A Case Series and the Clinical Implications of Vancomycin MIC Creep

  2022cites this paper
• Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring

  2022cites this paper
• Efficacy of teicoplanin in bloodstream infections caused by Enterococcus faecium: post-hoc analysis of a nationwide surveillance.

  2022cites this paper
• Population pharmacokinetics and dosing optimization of unbound teicoplanin in Chinese adult patients

  2022cites this paper
• Appropriate Use of Glycopeptide Antibiotics and Therapeutic Drug Monitoring for Invasive Infections

  2021cites this paper
• Teicoplanin physiologically based pharmacokinetic modeling offers a quantitative assessment of a theoretical influence of serum albumin and renal function on its disposition

  2021cites this paper
• Minireview: Mas-related G protein-coupled receptor X2 activation by therapeutic drugs

  2021cites this paper
• A fluorescence biosensor for therapeutic drug monitoring of vancomycin using in vivo microdialysis.

  2021cites this paper
• Enhanced loading dose of teicoplanin for three days is required to achieve a target trough concentration of 20 μg/mL in patients receiving continuous venovenous haemodiafiltration with a low flow rate.

  2021cites this paper
• Treatment of MRSA infections in India: Clinical insights from a Delphi analysis.

  2021cites this paper
• Incidence of acute kidney injury after teicoplanin- or vancomycin- and piperacillin/tazobactam combination therapy: A comparative study using propensity score matching analysis.

  2021cites this paper
• Clinical predictors of nephrotoxicity associated with teicoplanin: Meta‐analysis and meta‐regression

  2021cites this paper
• Comparison of risk of acute kidney injury between patients receiving the combination of teicoplanin and piperacillin/tazobactam versus vancomycin and piperacillin/tazobactam.

  2021cites this paper
• The Use of Vancomycin Versus Teicoplanin in Treating Febrile Neutropenia: A Meta-Analysis and Systematic Review

  2021cites this paper
• Comparison of the effect of teicoplanin and vancomycin on experimental methicillin-resistant staphylococcus aureus keratitis

  2021cites this paper
• Population Pharmacokinetics of Teicoplanin and Its Dosing Recommendations for Neutropenic Patients With Augmented Renal Clearance for Hematological Malignancies

  2021cites this paper
• Evaluation of a thrice weekly administration of teicoplanin in the outpatient setting: a retrospective observational multicentre study

  2021cites this paper
• Usage-evaluation study on Vancomycin among hospitalized pediatric patients: Experience from two tertiary care centers of Eastern India

  2021cites this paper
• Quantification of Teicoplanin Using the HPLC-UV Method for Clinical Applications in Critically Ill Patients in Korea

  2021cites this paper
• Teicoplanin versus β-lactam for febrile patients with Staphylococcus-like bacteremia: focus on methicillin-susceptible Staphylococcus aureus bacteremia

  2021cites this paper
• Determination of teicoplanin in human plasma by reverse micelle mediated dispersive liquid-liquid microextraction with high performance liquid chromatography.

  2021cites this paper
• Preparation of surface molecularly imprinted polymer and its application for the selective extraction of teicoplanin from water

  2021cites this paper
• Immunohistochemical localization and pharmacokinetics of the anti-MRSA drug teicoplanin in rat kidney using a newly developed specific antibody

  2021cites this paper
• MRGPRX2 and Adverse Drug Reactions

  2021cites this paper
• Comparison of teicoplanin versus vancomycin in combination with piperacillin-tazobactam or meropenem for the risk of acute kidney injury

  2021cites this paper
• Population Pharmacokinetics of Teicoplanin in Preterm and Term Neonates: Is It Time for a New Dosing Regimen?

  2020cites this paper
• Influence of Carbohydrate Residues on Antibacterial Activity of Vancomycin

  2020cites this paper
• Targeting host cell proteases as a potential treatment strategy to limit the spread of SARS‐CoV‐2 in the respiratory tract

  2020cites this paper
• Teicoplanin hypersensitivity in peri-operative anaphylaxis.

  2020cites this paper
• Population Pharmacokinetics and Model-Based Dosing Optimization of Teicoplanin in Pediatric Patients

  2020cites this paper
• Efficacy and Safety of Dalbavancin in Treatment of Gram-positive Bacterial Infections.

  2020cites this paper
• COVID-19 Therapeutic Options Under Investigation

  2020cites this paper
• Nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy

  2020cites this paper
• Cotrimoxazole Induced Steven Johnson Syndrome: A Case Report

  2020cites this paper
• Combinations of (lipo)glycopeptides with β-lactams against MRSA: susceptibility insights.

  2020cites this paper
• Adverse reactions to vancomycin and cross-reactivity with other antibiotics.

  2020cites this paper
• Nephrotoxicity of teicoplanin-based combination therapy: focus on piperacillin/tazobactam and other anti-pseudomonal β-lactams.

  2020cites this paper
• Comparison of breakthrough Gram‐positive cocci infection during vancomycin vs teicoplanin therapy in patients receiving haematopoietic stem cell transplantation

  2020cites this paper
• Expert consensus-based clinical practice guidelines management of intravascular catheters in the intensive care unit

  2020cites this paper
• Consensus Report on Diagnosis, Treatment and Prevention of Infective Endocarditis by Turkish Society of Cardiovascular Surgery (TSCVS), Turkish Society of Clinical Microbiology and Infectious Diseases (KLIMIK), Turkish Society of Cardiology (TSC), Turkish Society of Nuclear Medicine (TSNM), Turkish

  2020cites this paper
• Prospective Study of Irrational Prescription of Teicoplanin in a Large Academic Hospital: A Dilemma of Antimicrobial Resistance

  2020cites this paper
• Therapeutic Drug Level Monitoring of Teicoplanin in Korean Pediatric Patients with Normal versus Impaired Renal Function

  2020cites this paper
• The effect of N-acetylcysteine in a combined antibiofilm treatment against antibiotic-resistant Staphylococcus aureus.

  2020cites this paper
• Antimicrobial treatment of nosocomial meticillin-resistant (MRSA) pneumonia: current and future options

  2019cites this paper
• Incidence of teicoplanin adverse drug reactions among patients with vancomycin-associated adverse drug reactions and its risk factors

  2019cites this paper
• Development and validation of an ultra-high performance liquid chromatography - high resolution mass spectrometry method for the quantification of total and free teicoplanin in human plasma.

  2019cites this paper
• Systemic antibiotic treatment of chronic osteomyelitis in adults.

  2019cites this paper
• Comparative efficacy and safety of vancomycin versus teicoplanin in febrile neutropenic patients receiving hematopoietic stem cell transplantation

  2019cites this paper
• Antibiotic prophylaxis in orthopaedic surgery: Clinical practice guidelines or individualized prophylaxis?

  2019cites this paper
• Polymyxin Antibiotics: From Laboratory Bench to Bedside

  2019cites this paper
• Efficacy of teicoplanin monotherapy following initial standard therapy in Enterococcus faecalis infective endocarditis: a retrospective cohort study

  2019cites this paper
• Rational Combinations of Polymyxins with Other Antibiotics.

  2019cites this paper
• Resistance to Glycopeptide Antibiotics

  2019cites this paper
• Drug Utilization Evaluation of Vancomycin among Patients in Jafar Ibn Auf Pediatric Hospital, 2018

  2019cites this paper
• Nationwide Organism Susceptibility Patterns to Common Preoperative Prophylactic Antibiotics: What Are We Covering?

  2019cites this paper